Clinical Trial Update: A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating different doses of BI-765049 alone and in combination with Ezabenlimab in patients with advanced solid tumors expressing B7-H6; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastrointestinal Cancers
• Head and Neck Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• BI 765049 (BI-765049)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms | Phase 1 | Status: COMPLETED